Vitrolife Ab · OMXSTO:VITR
Vitrolife Ab — JP Morgan Healthcare Conference 2023
16 slides from Vitrolife Ab's conference presentation, January 2023
Slide 1: Vitrolife Group - Excellence in Reproductive Health
Slide 2: Vitrolife AB (publ) - JP Morgan Healthcare Conference
Vitrolife AB (publ) Patrik Tolf, CFO JP Morgan Healthcare Conference January 2023
Slide 3: 10-15% of all couples in fertile age suffer from fertility problems
10 – 15% of all couples in fertile age suffer from fertility problems
Slide 4: Vitrolife Group - Excellence in reproductive health
Vitrolife Group - Excellence in reproductive health Global presence in 110 markets Employees Sales per year Vitrolife AB (publ) listed on ~1,100 ~SEK 3 BN NASDAQ Best-in-class IVF Leadership in Stockholm Large Cap medical devices reproductive portfolio genetic testing services Founded 1994 Founded 2
Slide 5: Strong underlying growth with solid drivers in the IVF market
Strong underlaying growth with solid drivers in the IVF market • Delay in motherhood Demographic & social trends • Social acceptances and awareness of IVF • Lifestyle and social changes Top 5 markets worldwide North America • Improvement in IVF lab procedures (i.e. incubation system) Technical impro
Slide 6: Outcomes
Success rates “STEP BY STEP” Outcomes of ART Cycles Using Fresh Nondonor Eggs or IVF clinics way of Embryos working is essential 160,000 for a successful treatment 140,000 120,000 Intended retrievals 100,000 Retrievals Outcomes 138,328 Transfers 125,009 80,000 107,795 60,000 40,000 Live-birth delive
Slide 7: Innovative embryo evaluation and leading diagnostic tool to find window of implantation
Innovative embryo evaluation and leading diagnostic tool to find window of implantation Two of the strongest names within reproductive health into one platform to achieve successful treatment outcomes Two methods for embryo evaluation Combination improves successful treatment outcomes The right embr
Slide 8: Supporting clinics in every step of the reproductive health journey
Supporting clinics in every step of the reproductive health journey 8
Slide 9: Operating structure Vitrolife Group
Operating structure Vitrolife Group Executive Management and Group Functions Finance, Legal, IT, Strategy and HR & Sustainability Global Sales & Marketing Commercial excellence, Customer Services, Vitrolife Academy Media, cryo products, disposable devices and Incubation, time-lapse evaluation and la
Slide 10: Our financial objectives
Our financial objectives Profitable growth SALES GROWTH In local currencies, average 3 years +20% EBITDA MARGIN >30% NET DEBT/EBITDA <3 10
Slide 11: Sales and growth per market region, YTD Q3 2022
Sales and growth per market region, YTD Q3 2022 Total 2022 growth rate (local currencies) 238% 55% 40% 60% 86% Organic growth* (local currencies) 12% 3% 16% 18% 10% Sales (MSEK) 841 846 392 300 2,379 Share of Vitrolife 35% 36% 16% 13% Group’s sales * pro forma excluding Covid-19 tests 11
Slide 12: Long-term outlook
Long-term outlook Broadening the product and service offering Long-term market growth 5-10% in monetary terms Expansion of sales 12
Slide 13: Our vision with a purpose
Our vision with a purpose: to fulfil the dream of having a healthy baby 13
Slide 14: Thank you!
Thank you! Contact: Patrik Tolf, CFO, ptolf@vitrolife.com, +46 31 766 90 21 investors@vitrolife.com 14
Slide 15: Disclaimer
DISCLAIMER This presentation contains estimates and forward-looking statements, which reflect the Management’s current views with respect to the market, certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, there i
Slide 16: Slide 16
Vitrolife Group — JP Morgan Healthcare Conference 2023 on 6ix